PFEIZER’S new Covid vaccine can now be seen in production after Matt Hancock said Brits are likely to be among the first to receive it.
Footage shows the 90 per cent effective jab being produced on mass in a German lab, while scientists are on standby to roll it out before Christmas.
Read our coronavirus live blog for the latest news & updates
Scientists handle the ‘liquid hope’ as they prepare to roll out the vaccine[/caption]
Footage shows the vaccine being produced in a German lab[/caption]
It is packaged individually with hundreds of bottles seen being prepared[/caption]
Footage shows the liquid vaccine being handled by scientists before being individually packaged.
Hundreds of bottles of ‘liquid hope’ can be seen being produced in the lab, as optimism grows around its imminent roll-out.
Pfizer and its vaccine partner BioNTech announced on Monday that their coronavirus jab was more than 90 per cent effective in protecting people from Sars-CoV-2 – the virus that causes Covid-19.
The UK Government has already purchased 40million doses from drugs giant Pfizer – with ten million set to be made available before Christmas.
And Health Secretary Matt Hancock this morning revealed that he told the NHS to be ready to begin vaccinating people from the start of December – if the vaccine is proved to be safe.
He said “we’ll be among the first countries in the world to be able to start to do this.”
But he told Sky News that no vaccine will be deployed until the Government is “confident” of its safety.
Mr Hancock added: “I have asked them [the NHS] to be ready from the start of December.
“Of course, there are many hurdles that still need to be gone over and we haven’t seen the full safety data, and obviously that is critical.
“We won’t deploy a vaccine unless we can be confident in its clinical safety, but we also do need to be ready should a vaccine be licensed and get through all those hurdles and be ready to roll it out.”
Yet he stressed it was “absolutely a possibility” that doses would start being given out before Christmas.
Who will get the Covid vaccine first?
The Joint Committee on Vaccination and Immunisation (JCVI) has examined data on who suffers the worst outcomes from coronavirus and who is at highest risk of death.
Its interim guidance, which assumes the jab is safe and effective in all groups, says the order of priority should be:
- Older adults in a care home and care home workers
- All those aged 80 and over and health and social care workers, though they may move up the list
- Anyone 75 and over
- People aged 70 and over
- All those aged 65 and over
- High-risk adults under 65
- Moderate-risk adults under 65
- All those aged 60 and over
- All those 55 and over
- All those aged 50 and over
- The rest of the population, with priority yet to be determined.
The JCVI said the prioritisation could change if the first jab were not deemed suitable for, or effective in, older adults.
Care home residents, care workers, NHS staff and older people are expected to get the jab first – it may not come to the wider population until the new year.
Last night the PM said we have ordered enough doses to immunise a third of the population – and the UK are at the “front of the pack”.
Earlier, Mr Hancock said the military and NHS staff are on standby to roll out a Covid-19 vaccine across the UK from the start of December and will work “seven days a week”, with GPs, new vaccination centres and pharmacists all playing a role.
Pop-up vaccination clinics are also expected to be used in some areas.
Mr Hancock said there were many hurdles to overcome before the “vast task” of vaccination could begin, including thorough examination of clinical trial data.
Pfizer said yesterday it will apply within weeks to the FDA in the US and the EMA and MHRA in Europe and the UK for emergency approval.
Most read in News
The breakthrough has taken scientists ten months, compared to the usual ten to 15 years to develop a vaccine.
Pfizer chairman and chief executive Dr Albert Bourla said yesterday: “Today is a great day for science and humanity.
“We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.”